Isomorphic Labs in early talks to raise funding at up to $50 billion valuation
AI drug discovery startup Isomorphic Labs is in early negotiations to raise new capital at a valuation between $40 billion and $50 billion, according to reports.
Isomorphic Labs, the AI-powered drug discovery startup spun out of Alphabet's Google DeepMind, is in early talks to raise fresh funding at a valuation of at least $40 billion, Bloomberg reported citing people familiar with the matter. Additional reports indicate that the valuation could reach as high as $50 billion.[1][2][3][4][5]
The discussions follow a $2.1 billion Series B financing round completed five months earlier. That round was led by Thrive Capital, alongside participation from Alphabet and sovereign funds from Singapore, the United Arab Emirates, and the United Kingdom. Demis Hassabis stepped down as Google DeepMind CEO in August but continues to lead Isomorphic Labs while also serving as Alphabet's chief scientist.[5]
Isomorphic Labs leverages AlphaFold, the breakthrough AI model that solved 3D protein structure prediction in 2020 and earned Hassabis and John Jumper the 2024 Nobel Prize in Chemistry. The company uses the technology to design drugs, starting with treatments for cancer and immune disorders, and has secured pharmaceutical partnerships with Eli Lilly and Novartis. Crypto Briefing noted that the surge in valuation underscores growing investor appetite for AI drug discovery even though Isomorphic Labs still lacks clinical data.[5][6]
Key facts
- Isomorphic Labs is in early talks to secure funding at a valuation of at least $40 billion, potentially reaching up to $50 billion.
- Isomorphic Labs previously raised a $2.1 billion Series B led by Thrive Capital, with Alphabet and sovereign funds from Singapore, the UAE, and the UK participating.
- Demis Hassabis stepped down as Google DeepMind's CEO in August but continues to lead Isomorphic Labs and serve as Alphabet's chief scientist.
- The startup uses AlphaFold technology to design drugs, focusing initially on cancer and immune disorders.
- Eli Lilly and Novartis are existing pharmaceutical partners of Isomorphic Labs.
- Isomorphic Labs' valuation discussions come despite the startup lacking clinical data.
- AlphaFold 2 cracked protein folding in 2020, earning Demis Hassabis and John Jumper the 2024 Nobel Prize in Chemistry.
Sources · 5 sources
- MT
MTS@MTSlivePost on X ·
SITUATION DETECTED: Isomorphic Labs, Demis Hassabis’s AI drug-discovery spinout from Google DeepMind, is in early talks to raise at a valuation of at least $40 billion, and possibly $50 billion, per Bloomberg.
Open source - BL
Bloomberg@businessPost on X ·
Isomorphic Labs, an AI-powered drug discovery startup spun out of Alphabet’s Google DeepMind, is in early talks to raise new funds at a valuation of at least $40 billion, according to people familiar with the effort. https://t.co/gYxA73ycfz
Open source - TE
Techmeme@TechmemePost on X ·
Sources: Isomorphic Labs, an AI drug discovery startup spun out of Google DeepMind, is in early talks to raise funds at a valuation of at least $40B (Bloomberg) (Visit Techmeme dot com for the link and full context!)
Open source - SI
SiliconANGLE@SiliconANGLEPost on X ·
Alphabet spinoff Isomorphic Labs reportedly raising funding at up to $50B valuation https://t.co/kO01VMtY6F
Open source - MT
MTS@MTSlivePost on X ·
SITUATION EXPLAINED: Isomorphic Labs, Demis Hassabis's AlphaFold spinout, is in talks to raise at a $40 to $50 billion valuation. • It raised a $2.1B Series B just 5 months ago, led by Thrive Capital, with Alphabet and sovereign funds from Singapore, the UAE and the UK • Hassabis stepped down as Google DeepMind CEO in August but still runs Isomorphic, on top of being Alphabet's chief scientist • AlphaFold 2 cracked protein folding in 2020, predicting a protein's 3D shape from its amino acids, and won Hassabis and John Jumper the 2024 Nobel Prize in Chemistry • Isomorphic uses AlphaFold to design drugs with AI, starting with cancer and immune disorders • Weight-loss drugs alone made Eli Lilly a $1T company, so AI that works across many drug categories could be huge. Lilly and Novartis are already Isomorphic partners @theojaffee: "If AI can actually help with drug discovery meaningfully, and Isomorphic Labs is able to capture some of this value, and it's able to do it across more fields than just one, then it could be huge."
Open source - CB
Crypto BriefingArticle ·
Isomorphic Labs reportedly seeks funding at a valuation of at least $40 billion Isomorphic Labs' valuation surge highlights the growing investor confidence in AI-driven drug discovery, despite lacking clinical data. The post Isomorphic Labs reportedly seeks funding at a valuation of at least $40 billion appeared first on Crypto Briefing .
Open source